Industry News

HTG Molecular Diagnostics, Inc., a provider of instruments and reagents for molecular profiling applications, today announced that Ann F. Hanham, Ph.D. has been appointed to its Board of Directors.. Ann Hanham is a senior health care executive with experience working with both private and public companies. Hanham possesses a diverse background in global clinical and regulatory development, finance, and corporate strategy."/>
Dr. Ann Hanham Joins HTG Molecular Diagnostics’ Board of Directors
Teva Pharmaceutical Industries Ltd. is seeking to offload. The Israeli company is required to sell the portfolio to comply with the EU antitrust regular's conditions for approving the acquisition of the generics division of Allergan. Teva completed the $40 billion acquisition earlier this month."/>
BRIEF: Intas, Auribindo bid $1b for Teva UK portfolio [Globes, Tel Aviv, Israel]
Shufersal Ltd. manage to break Similac and Materna's duopoly on infant formula? Today, Shufersal launched its infant formula under the brand name Shufersal Baby. The series of infant formula products is manufactured by US drug giant Perrigo, one of the four US manufacturers with an US Food and Drug Administration certification and the only one which is ISO quality standard certified."/>
Shufersal launches own-brand infant formula [Globes, Tel Aviv, Israel]
Providence Service Corporation in the creation of a strategic partnership with Frazier Healthcare Partners in Matrix Medical Network. Under the terms of the transaction, Frazier will own a 60% equity interest in Matrix and Providence will retain a 40% equity interest in Matrix and have representatives on..."/>
TripleTree Advises Providence Service Corporation on the Formation of a Strategic Partnership with Frazier Healthcare Partners in Matrix Medical Network
Inovio Pharmaceuticals in Plymouth Meeting said Monday it has begun a clinical study of its experimental Zika vaccine in 160 healthy adult volunteers in Puerto Rico, where the virus outbreak has been declared a public health emergency. The Centers for Disease Control and Prevention has estimated Zika will infect more than 25 percent of the Puerto Rican population by the end of the year, Inovio said. The study in Puerto Rico involves 80 volunteers who will receive the..."/>
Inovio will test its Zika vaccine in Puerto Rico [The Philadelphia Inquirer]
Shire plc today announced that Xiidra™ 5%, a twice-daily prescription eye drop indicated for the treatment of both the signs and symptoms of dry eye disease, is now available by prescription in the United States. An estimated 16 million adults in the U.S. are diagnosed with dry eye, a disease associated with inflammation that may eventually lead to damage to the surface of the eye. An eye care professional can diagnose dry eye disease based on..."/>
Shire's First Prescription Eye Drop, Xiidra™ (lifitegrast ophthalmic solution) 5% Is Now Available in the U.S.
Silicom with a price target of $43.00, On Track Innovations with a price target of $2.00, Intellecheck Mobilisa with a price target of $3.00 and Catasys with a price target of $3.00. Reports can be viewed at: If you have any questions, contact:."/>
Joseph Gunnar & Co., LLC Head of Equity Research Initiates Coverage with a Buy Rating on Silicom Ltd., On Track Innovations Ltd., Intellecheck Mobilisa, Inc. and Catasys, Inc.
IMS Health, but Chief Operating Officer Kevin Gordon will be departing after the two companies combine. Pike's new role will include heading the core contract research organization, or CRO, operations, according to the two companies' announcement of key executive positions released Monday. CROs help drug companies conduct clinical..."/>
Quintiles CEO Tom Pike will have operating role after merger [The News & Observer (Raleigh, N.C.)]
Ossur Hf : Transactions in relation to share buyback program
Teva Pharmaceutical Industries Ltd. announced today that it will host a conference call and live webcast along with a slide presentation on Friday, September 9, 2016 at 8:00 a.m. ET to communicate an overview of the future prospects of Teva Generics business following the close of the Actavis generics deal. The presentation will focus on strategy, commercial, portfolio and R&D capabilities and will include an overview of specific pipeline opportunities in 2017..."/>
Teva to Host Generic Medicines Business Overview on September 9, 2016
Cotiviti Holdings Inc. a leading provider of analytics-driven payment accuracy solutions primarily focused on the healthcare industry, announced today that it will attend the Morgan Stanley 2016 Global Healthcare Conference on Monday, September 12, 2016, at the Grand Hyatt Hotel in New York. Doug Williams, Chief Executive Officer, and Steve Senneff, Chief Financial Officer, will participate in a fireside chat at 2:50 p.m. Eastern Time. A live audio webcast will be..."/>
Cotiviti to Participate in Morgan Stanley 2016 Global Healthcare Conference
Ampio Pharmaceuticals, Inc. today announced that it has entered into a securities purchase agreement with an institutional investor providing for the registered sale of 5,000,000 shares of common stock and accompanying warrants to purchase up to 5,000,000 shares of common stock with an exercise price of $1.00 per share, at a combined purchase price of $0.75 per share and accompanying warrant. The gross proceeds to the Company will..."/>
Ampio Pharmaceuticals, Inc. Announces Pricing of Registered Direct Offering
MiMedx Group, Inc., the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced today an update to its intellectual property portfolio. Since the last update of the MiMedx patent portfolio in the Company's November 19,..."/>
MiMedx Awarded Six New U.S. Patents with Five Awarded for its Amniotic Membrane Allografts and One Awarded for its CollaFix™ Technology
Resverlogix Corp. today announced that on Sunday, August 28, 2016, at the European Society of Cardiology Congress in Rome, Italy, the Company hosted a symposium entitled "A novel approach for high CV risk patients with diabetes: The potential of epigenetics.""/>
Resverlogix Hosts Symposium to Discuss the Role of BET-inhibition in Modifying Cardiovascular Risk at the ESC Congress in Rome, Italy
Resverlogix Corp. today announced that on Sunday, August 28, 2016, at the European Society of Cardiology Congress in Rome, Italy, the Company hosted a symposium entitled "A novel approach for high CV risk patients with diabetes: The potential of epigenetics.""/>
Resverlogix Hosts Symposium to Discuss the Role of BET-inhibition in Modifying Cardiovascular Risk at the ESC Congress in Rome, Italy
HemaCare sponsors CAR-TCR Summit in support of researchers developing cell therapies utilizing T-cell receptor modifications. LOS ANGELES---- HemaCare Corporation, a leader in cell and tissue collection, processing, and cell therapy solutions, today announced that it is supporting the 2016 CAR-TCR Summit to be hosted at the Hyatt Regency in Boston September 13-15 th. This summit is the premiere meeting attended by 400 scientific and clinical leaders working on the..."/>
HemaCare Supports 2016 CAR-TCR Summit
IMS Health Holdings, Inc. and contract research provider Quintiles Transnational Holdings Inc. have determined key senior management roles in the future Quintiles IMS corporate leadership team, subject to the completion of the merger, the companies said. Senior functional leaders reporting to chairman and chief executive officer Ari Bousbib will include EVP and chief financial officer..."/>
IMS Health and Quintiles Name Key Officers for Merged Firm
Nymox Pharmaceutical Corporation lead drug fexapotide which has been in development for over a decade and which has been tested by expert clinical trial investigative teams in over 70 distinguished clinical trial centers throughout the US, has been found after 7 years of prospective placebo controlled double blind studies of treatment of 995 U.S...."/>
Nymox's New Phase 3 Long-Term U.S. Results For Prostate Enlargement Drug Fexapotide Show 
BioTelemetry, Inc., the leading wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, is pleased to announce that the Company has received CE mark approval of its Holter analysis software. The software can be used either on a stand-alone basis or in combination with the Company’ s family of digital Holter recorders.. Joseph H. Capper, President and Chief Executive Officer of..."/>
BioTelemetry, Inc. announces CE mark approval of Holter analysis software

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Consumer Discretionary658 Articles
Information Technology594 Articles
Financials510 Articles
Health Care353 Articles
Industrials351 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at